These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15851403)

  • 1. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
    Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
    Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
    Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
    Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
    MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
    Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
    Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
    Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
    Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
    Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
    Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
    Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
    Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
    Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seliciclib in malignancies.
    Aldoss IT; Tashi T; Ganti AK
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
    McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
    Int J Cancer; 2002 Dec; 102(5):463-8. PubMed ID: 12432547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
    Coley HM; Shotton CF; Kokkinos MI; Thomas H
    Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
    Bogner C; Ringshausen I; Schneller F; Fend F; Quintanilla-Martinez L; Häcker G; Goetze K; Oostendorp R; Peschel C; Decker T
    Br J Haematol; 2003 Jul; 122(2):260-8. PubMed ID: 12846895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
    Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
    Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
    Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
    Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
    Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
    Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes.
    Atanasova G; Jans R; Zhelev N; Mitev V; Poumay Y
    Biochem Pharmacol; 2005 Sep; 70(6):824-36. PubMed ID: 16011834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
    Lo RK; Kwong YL
    Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
    Kapasi AJ; Spector DH
    J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.